Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 2
2023 8

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean labarca c[au] (61 results)?
Belantamab mafodotin in multiple myeloma.
Martino EA, Bruzzese A, Iaccino E, Labanca C, Mendicino F, Mimmi S, Lucia E, Olivito V, Neri A, Morabito F, Vigna E, Gentile M. Martino EA, et al. Among authors: labanca c. Expert Opin Biol Ther. 2023 May 27:1-5. doi: 10.1080/14712598.2023.2218543. Online ahead of print. Expert Opin Biol Ther. 2023. PMID: 37227998 No abstract available.
Teclistamab-cqyv in multiple myeloma.
Martino EA, Bruzzese A, Labanca C, Mendicino F, Lucia E, Olivito V, Neri A, Morabito F, Vigna E, Gentile M. Martino EA, et al. Among authors: labanca c. Eur J Haematol. 2023 Oct 17. doi: 10.1111/ejh.14121. Online ahead of print. Eur J Haematol. 2023. PMID: 37848191 Review.
Tagraxofusp in myeloid malignancies.
Bruzzese A, Martino EA, Labanca C, Mendicino F, Lucia E, Olivito V, Neri A, Imovilli A, Morabito F, Vigna E, Gentile M. Bruzzese A, et al. Among authors: labanca c. Hematol Oncol. 2023 Oct 17. doi: 10.1002/hon.3234. Online ahead of print. Hematol Oncol. 2023. PMID: 37846131 Review.
Ivosidenib in acute myeloid leukemia.
Bruzzese A, Labanca C, Martino EA, Mendicino F, Lucia E, Olivito V, Neri A, Imovilli A, Morabito F, Vigna E, Gentile M. Bruzzese A, et al. Among authors: labanca c. Expert Opin Pharmacother. 2023 Oct 24:1-8. doi: 10.1080/14656566.2023.2272659. Online ahead of print. Expert Opin Pharmacother. 2023. PMID: 37874005 Review.
Zanubrutinib for the treatment of chronic lymphocytic leukemia.
Bruzzese A, Martino EA, Labanca C, Mendicino F, Lucia E, Olivito V, Neri A, Morabito F, Vigna E, Gentile M. Bruzzese A, et al. Among authors: labanca c. Expert Opin Pharmacother. 2023 Sep-Dec;24(13):1409-1413. doi: 10.1080/14656566.2023.2229734. Epub 2023 Jun 26. Expert Opin Pharmacother. 2023. PMID: 37350553 No abstract available.
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review.
Di Martino MT, Arbitrio M, Caracciolo D, Cordua A, Cuomo O, Grillone K, Riillo C, Caridà G, Scionti F, Labanca C, Romeo C, Siciliano MA, D'Apolito M, Napoli C, Montesano M, Farenza V, Uppolo V, Tafuni M, Falcone F, D'Aquino G, Calandruccio ND, Luciano F, Pensabene L, Tagliaferri P, Tassone P. Di Martino MT, et al. Among authors: labanca c. Mol Ther Nucleic Acids. 2022 Feb 11;27:1191-1224. doi: 10.1016/j.omtn.2022.02.005. eCollection 2022 Mar 8. Mol Ther Nucleic Acids. 2022. PMID: 35282417 Free PMC article. Review.
Glasdegib for the treatment of acute myeloid leukemia.
Bruzzese A, Martino EA, Labanca C, Mendicino F, Lucia E, Olivito V, Fimognari F, Neri A, Morabito F, Vigna E, Gentile M. Bruzzese A, et al. Among authors: labanca c. Expert Opin Pharmacother. 2023 Sep-Dec;24(14):1537-1543. doi: 10.1080/14656566.2023.2232301. Epub 2023 Jul 3. Expert Opin Pharmacother. 2023. PMID: 37392098
The impact of PARP inhibitors in the whole scenario of Ovarian Cancer management: a Systematic Review and Network Meta-Analysis.
Staropoli N, Ciliberto D, Luciano F, Napoli C, Costa M, Rossini G, Arbitrio M, Labanca C, Riillo C, Del Giudice T, Crispino A, Salvino A, Galvano A, Russo A, Tassone P, Tagliaferri P. Staropoli N, et al. Among authors: labanca c. Crit Rev Oncol Hematol. 2023 Dec 6:104229. doi: 10.1016/j.critrevonc.2023.104229. Online ahead of print. Crit Rev Oncol Hematol. 2023. PMID: 38065404 Review.
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics.
Staropoli N, Arbitrio M, Salvino A, Scionti F, Ciliberto D, Ingargiola R, Labanca C, Agapito G, Iuliano E, Barbieri V, Cucè M, Zuccalà V, Cannataro M, Tassone P, Tagliaferri P. Staropoli N, et al. Among authors: labanca c. Biomedicines. 2022 May 23;10(5):1210. doi: 10.3390/biomedicines10051210. Biomedicines. 2022. PMID: 35625946 Free PMC article.